½ÃÀ庸°í¼­
»óǰÄÚµå
1475219

¼¼°èÀÇ °©»ó¼± Áúȯ Ä¡·á ½ÃÀå Á¶»ç º¸°í¼­ : »ê¾÷ ºÐ¼®, ±Ô¸ð, Á¡À¯À², ¼ºÀå, µ¿Çâ, ¿¹Ãø(2024-2032³â)

Global Thyroid Gland Disorder Treatment Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Value Market Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 222 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ °©»ó¼± Áúȯ Ä¡·á ½ÃÀå ¼ö¿ä´Â Á¶»ç ±â°£ 2024³âºÎÅÍ 2032³â±îÁö CAGR 4.29%¿¡ À̸¦ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù.

°©»ó¼± Áúȯ Ä¡·á¶õ °©»ó¼± ±â´É ÀúÇÏÁõ, °©»ó¼± ±â´É Ç×ÁøÁõ, °©»ó¼± °áÀý, °©»ó¼±Á¾, °©»ó¼±¾Ï, ÀÚ°¡¸é¿ª¼º °©»ó¼± Áúȯ(ÇϽøðÅä °©»ó¼±¿°, ¹Ù¼¼µµ¿ìº´ µî) µî ´Ù¾çÇÑ °©»ó¼± Áúȯ °ü¸®¸¦ ¸ñÀûÀ¸·Î ÇÏ´Â ÀÇ·á °³ÀÔ°ú Ä¡·á¸¦ ¸»ÇÕ´Ï´Ù. Ä¡·á ¿É¼ÇÀº ¾à¹° ¿ä¹ý(°©»ó¼± È£¸£¸ó º¸Ãæ ¿ä¹ý, Ç× °©»ó¼± ¾à¹° µî), ¹æ»ç¼º ¿ä¿Àµå ¿ä¹ý, °©»ó¼± ÀýÁ¦¼ú(°©»ó¼±ÀÇ ¼ö¼ú ÀýÁ¦), ¶óµð¿À ÆÄ ¼ÒÀÛ¼ú, ¿¡Åº¿Ã ¼ÒÀÛ¼ú, °©»ó¼±¾Ï Ç¥Àû ¿ä¹ý µîÀÌ ÀÖ½À´Ï´Ù. Ä¡·á¹ýÀÇ ¼±ÅÃÀº °©»ó¼± Áúȯ À¯Çü°ú ÁßÁõµµ, ³ªÀÌ, Àü½Å °Ç°­ »óÅÂ, ¼±È£¿Í °°Àº °³º° ȯÀÚ ¿äÀο¡ µû¶ó ´Þ¶óÁý´Ï´Ù.

½ÃÀå ¿ªÇÐ

°©»ó¼± ±â´É ÀúÇÏÁõ, °©»ó¼± ±â´É Ç×ÁøÁõ, °©»ó¼± °áÀýÀ» Æ÷ÇÔÇÑ °©»ó¼± ÁúȯÀÇ ÀÌȯÀ² Áõ°¡´Â Áõ»óÀ» °ü¸®ÇÏ°í °©»ó¼± È£¸£¸ó ¼öÁØÀ» Á¤»óÈ­Çϰí ȯÀÚÀÇ »îÀÇ ÁúÀ» Çâ»ó½ÃŰ´Â È¿°úÀûÀÎ Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. Àα¸ °í·ÉÈ­, ¿ä¿Àµå °áÇÌ, ÀÚ°¡¸é¿ªÁúȯ, ȯ°æ¿À¿°¹°Áú µîÀÇ ¿äÀÎÀÌ °©»ó¼±ÁúȯÀÇ ºÎ´ã Áõ°¡¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÀÇ·á±â¼ú°ú Áø´Ü µµ±¸ÀÇ Áøº¸´Â Á¤È®ÇÑ Áø´Ü°ú °³º° ȯÀÚÀÇ Çʿ信 ¸Â´Â °³ÀÎÈ­µÈ Ä¡·á Á¢±Ù¹ýÀ» °¡´ÉÇÏ°Ô ÇÏ°í °©»ó¼± Áúȯ Ä¡·á¹ýÀÇ Çõ½ÅÀ» ÃßÁøÇϰí ÀÖ½À´Ï´Ù. °Ô´Ù°¡, ÀÇ·á¿¡¼­ÀÇ È¯ÀÚ Áß½ÉÀÇ Äɾî, ÀÇ»ç°áÁ¤ÀÇ °øÀ¯, ÀüÀÎÀû °ü¸® ¾îÇÁ·ÎÄ¡ÀÇ Áß½ÃÀÇ °íÁ¶´Â ÃÖÀûÀÇ °á°ú¸¦ ¾ò±â À§Çؼ­ ¾àÄ¡·á, »ýȰ ½À°üÀÇ °³¼±, ½Ä»ç °³ÀÔ, º¸¿Ï ¿ä¹ýÀ» Á¶ÇÕÇÑ ÁýÇÐ Àû Ä¡·á Àü·«ÀÇ Ã¤¿ëÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

¶ÇÇÑ È¯ÀÚ ±³À° ÀÌ´Ï¼ÅÆ¼ºê, ±¤°í Ȱµ¿, °øÁß º¸°Ç Ä·ÆäÀÎÀº °©»ó¼± Áúȯ, Áõ»ó, À§Çè ¿äÀÎ ¹× Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ÀνÄÀ» ³ôÀ̰í ȯÀÚ°¡ Àû½Ã¿¡ ÁøÂûÀ» ¹Þ°í ó¹æµÈ Ä¡·á ¿ä¹ýÀ» ÁؼöÇÒ ¼ö ÀÖ°Ô ÇÕ´Ï´Ù. °©»ó¼± ÁúȯÀÌ °øÁß º¸°Ç¿¡ ½É°¢ÇÑ °ü½É»ç¶ó´Â ÀνÄÀÌ ³ô¾ÆÁö°í Á¾ÇÕÀûÀ̰í ÅëÇÕÀûÀÎ ÀÇ·á ¼­ºñ½º¿¡ ´ëÇÑ ¼ö¿ä°¡ ³ô¾ÆÁö°í Àֱ⠶§¹®¿¡ °©»ó¼± Áúȯ Ä¡·á ½ÃÀåÀº ÀÇ·á Á¦°ø¾÷ü¿Í °ø°³ ȸ»ç°¡ ȯÀÚÀÇ ÁøÈ­ÇÏ´Â ¿ä±¸¿¡ ´ëÀÀÇØ, ÀÓ»ó °á°ú¸¦ °³¼±Çϱâ À§Çؼ­ Çõ½ÅÀûÀÎ ´ëó¸¦ ½Ç½ÃÇϰí ÀÖ¾î, ÇâÈÄ¿¡µµ ¼ºÀåÀ» °è¼ÓÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±×·¯³ª »õ·Î¿î Ä¡·á¹ý°ú Á¦ÇüÀ» µÑ·¯½Ñ ±ÔÁ¦ Àå¾Ö¹°°ú ¾ÈÀü¼º¿¡ ´ëÇÑ ¿ì·Á´Â ÇâÈÄ ¸î ³âµ¿¾È °©»ó¼± Áúȯ Ä¡·á ½ÃÀåÀÇ ¼ºÀå¿¡ ¿µÇâÀ» ÁÙ ¼ö ÀÖ½À´Ï´Ù. °Ô´Ù°¡ Á¦³×¸¯ ´ëüǰ°úÀÇ °æÀï °ÝÈ­¿Í °¡°Ý ¾Ð·ÂÀº ½ÃÀå È®´ë¸¦ ¹æÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

Á¶»ç º¸°í¼­´Â Porter's Five Forces ¸ðµ¨, ½ÃÀå ¸Å·Â ºÐ¼®, ¹ë·ùüÀÎ ºÐ¼®À» ´Ù·ç°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µµ±¸´Â ¾÷°èÀÇ ±¸Á¶¸¦ ¸íÈ®ÇÏ°Ô ÆÄ¾ÇÇÏ°í ¼¼°è ¼öÁØ¿¡¼­ °æÀïÀÇ ¸Å·ÂÀ» Æò°¡ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ¶ÇÇÑ, ÀÌ·¯ÇÑ µµ±¸´Â ¼¼°èÀÇ °©»ó¼± Áúȯ Ä¡·á ½ÃÀå¿¡¼­ °¢ ºÎ¹®À» Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. °©»ó¼± Áúȯ Ä¡·á »ê¾÷ÀÇ ¼ºÀå°ú µ¿ÇâÀº ÀÌ Á¶»ç¿¡ ´ëÇÑ Àü¹ÝÀûÀÎ Á¢±Ù¹ýÀ» ¼³¸íÇÕ´Ï´Ù.

½ÃÀå ¼¼ºÐÈ­

°©»ó¼± Áúȯ Ä¡·á ½ÃÀå º¸°í¼­ÀÇ ÀÌ ¼½¼Ç¿¡¼­´Â ±¹°¡ ¹× Áö¿ª ¼öÁØ ºÎ¹®¿¡ ´ëÇÑ ÀÚ¼¼ÇÑ µ¥ÀÌÅ͸¦ Á¦°øÇϹǷΠÀü·«°¡´Â ÇâÈÄ ±âȸ¿¡¼­ °¢ Á¦Ç° ¹× ¼­ºñ½ºÀÇ ´ë»ó °èÃþÀ» ½Äº°ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù.

ÀûÀÀÁõº°

  • °©»ó¼± ±â´É ÀúÇÏÁõ
  • °©»ó¼± ±â´É Ç×ÁøÁõ

Åõ¿© °æ·Îº°

  • °æ±¸
  • Á¤¸Æ³»
  • ±âŸ

À¯Åë ä³Îº°

  • µµ¸Å¾÷ü ¹× ÆÇ¸Å¾÷ÀÚ
  • ¼Ò¸Å üÀÎ
  • ¿Â¶óÀÎ ÆÇ¸Å
  • ±âŸ

Áö¿ª ºÐ¼®

ÀÌ ¼½¼Ç¿¡¼­´Â ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«¿¡¼­ °©»ó¼± Áúȯ Ä¡·á ½ÃÀåÀÇ ÇöÀç ¹× ¹Ì·¡ ¼ö¿ä¸¦ °­Á¶ÇÏ´Â Áö¿ª Àü¸ÁÀ» ´Ù·ì´Ï´Ù. ¶ÇÇÑ ÀÌ º¸°í¼­´Â ¸ðµç ÁÖ¿ä Áö¿ª¿¡¼­ °³º° ¿ëµµ ºÎ¹® ¼ö¿ä, ÃßÁ¤ ¹× ¿¹Ãø¿¡ ÁßÁ¡À» µÓ´Ï´Ù.

¸ÂÃ㠿䱸»çÇ×ÀÌ ÀÖ´Â °æ¿ì Google¿¡ ¹®ÀÇÇϼ¼¿ä. ´ç»çÀÇ ¼³¹®Á¶»çÆÀÀº °í°´ÀÇ ¿ä±¸¿¡ µû¶ó ¸ÂÃãÇü º¸°í¼­¸¦ Á¦°øÇÒ ¼ö ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå ÁÖ¿ä ¿ä¾à

  • ½ÃÀåÀÇ ÇÏÀ̶óÀÌÆ®
  • ¼¼°è ½ÃÀå ÇöȲ

Á¦3Àå °©»ó¼± Áúȯ Ä¡·á : »ê¾÷ ºÐ¼®

  • ¼­¹® : ½ÃÀå ¿ªÇÐ
  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
  • ½ÃÀå ±âȸ
  • »ê¾÷ µ¿Çâ
  • Porter's Five Forces ºÐ¼®
  • ½ÃÀå ¸Å·Âµµ ºÐ¼®

Á¦4Àå ¹ë·ùüÀÎ ºÐ¼®

  • ¹ë·ùüÀÎ ºÐ¼®
  • ¿øÀç·á ºÐ¼®
    • ¿øÀç·á ¸®½ºÆ®
    • ¿øÀç·á Á¦Á¶¾÷ü À϶÷
    • ÁÖ¿ä ¿øÀç·áÀÇ °¡°Ý µ¿Çâ
  • ÀáÀçÀû ¹ÙÀ̾î À϶÷
  • ¸¶ÄÉÆÃ Ã¤³Î
    • Á÷Á¢ ¸¶ÄÉÆÃ
    • °£Á¢ ¸¶ÄÉÆÃ
    • ¸¶ÄÉÆÃ Ã¤³Î ¹ßÀü µ¿Çâ

Á¦5Àå ¼¼°èÀÇ °©»ó¼± Áúȯ Ä¡·á ½ÃÀå ºÐ¼® : ÀûÀÀÁõº°

  • ÀûÀÀÁõº° °³¿ä
  • ½ÇÀû µ¥ÀÌÅÍ ¹× ¿¹Ãø µ¥ÀÌÅÍ
  • ÀûÀÀÁõº° ºÐ¼®
  • °©»ó¼± ±â´É ÀúÇÏÁõ
  • °©»ó¼± ±â´É Ç×ÁøÁõ

Á¦6Àå ¼¼°èÀÇ °©»ó¼± Áúȯ Ä¡·á ½ÃÀå ºÐ¼® : Åõ¿© °æ·Îº°

  • Åõ¿© °æ·Îº° °³¿ä
  • ½ÇÀû µ¥ÀÌÅÍ ¹× ¿¹Ãø µ¥ÀÌÅÍ
  • Åõ¿© °æ·Îº° ºÐ¼®
  • °æ±¸
  • Á¤¸Æ³»
  • ±âŸ

Á¦7Àå ¼¼°èÀÇ °©»ó¼± Áúȯ Ä¡·á ½ÃÀå ºÐ¼® : À¯Åë ä³Îº°

  • À¯Åë ä³Îº° °³¿ä
  • ½ÇÀû µ¥ÀÌÅÍ ¹× ¿¹Ãø µ¥ÀÌÅÍ
  • À¯Åë ä³Îº° ºÐ¼®
  • µµ¸Å¾÷ü ¹× ÆÇ¸Å¾÷ÀÚ
  • ¼Ò¸Å üÀÎ
  • ¿Â¶óÀÎ À¯Åë
  • ±âŸ

Á¦8Àå ¼¼°èÀÇ °©»ó¼± Áúȯ Ä¡·á ½ÃÀå ºÐ¼® : Áö¿ªº°

  • Áö¿ªº° Àü¸Á
  • ¼­¹®
  • ºÏ¹ÌÀÇ ¸ÅÃ⠺м®
    • °³¿ä, ½ÇÀû ¹× ¿¹Ãø
    • ºÏ¹Ì : ºÎ¹®º°
    • ºÏ¹Ì : ±¹°¡º°
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
  • À¯·´ÀÇ ¸ÅÃ⠺м®
    • °³¿ä, ½ÇÀû ¹× ¿¹Ãø
    • À¯·´ : ºÎ¹®º°
    • À¯·´ : ±¹°¡º°
    • ¿µ±¹
    • ÇÁ¶û½º
    • µ¶ÀÏ
    • ÀÌÅ»¸®¾Æ
    • ·¯½Ã¾Æ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ¸ÅÃ⠺м®
    • °³¿ä, ½ÇÀû ¹× ¿¹Ãø
    • ¾Æ½Ã¾ÆÅÂÆò¾ç : ºÎ¹®º°
    • ¾Æ½Ã¾ÆÅÂÆò¾ç : ±¹°¡º°
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • Çѱ¹
    • È£ÁÖ
    • µ¿³²¾Æ½Ã¾Æ
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«ÀÇ ¸ÅÃ⠺м®
    • °³¿ä, ½ÇÀû ¹× ¿¹Ãø
    • ¶óƾ¾Æ¸Þ¸®Ä« : ºÎ¹®º°
    • ¶óƾ¾Æ¸Þ¸®Ä« : ±¹°¡º°
    • ºê¶óÁú
    • ¾Æ¸£ÇîÆ¼³ª
    • Æä·ç
    • Ä¥·¹
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ¸ÅÃ⠺м®
    • °³¿ä, ½ÇÀû ¹× ¿¹Ãø
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ºÎ¹®º°
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ±¹°¡º° À϶÷
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
    • À̽º¶ó¿¤
    • ³²¾ÆÇÁ¸®Ä«
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦9Àå °©»ó¼± Áúȯ Ä¡·á ±â¾÷°æÀï ±¸µµ

  • °©»ó¼± Áúȯ Ä¡·á ½ÃÀåÀÇ °æÀï
  • Á¦ÈÞ, Çù·Â ¹× °è¾à
  • ÇÕº´ ¹× Àμö
  • ½ÅÁ¦Ç° Ãâ½Ã
  • ±âŸ °³¹ß

Á¦10Àå ±â¾÷ ÇÁ·ÎÆÄÀÏ

  • ÁÖ¿ä ±â¾÷ÀÇ ½ÃÀå Á¡À¯À² ºÐ¼®
  • ½ÃÀå ÁýÁßµµ
  • Abbott
  • Pfizer
  • Lannett Company Inc.
  • GlaxoSmithKline
  • Merck KGaA
  • Mylan NV
  • AbbVie Inc.
  • Amgen.
AJY 24.05.20

The global demand for Thyroid Gland Disorder Treatment Market is presumed to reach with a CAGR of 4.29% under the study period 2024 - 2032.

Thyroid gland disorder treatment refers to medical interventions and therapies aimed at managing various thyroid conditions such as hypothyroidism, hyperthyroidism, thyroid nodules, goiter, thyroid cancer, and autoimmune thyroid disorders (e.g., Hashimoto's thyroiditis, Graves' disease). Treatment options may include medication (e.g., thyroid hormone replacement therapy, antithyroid medications), radioactive iodine therapy, thyroidectomy (surgical removal of the thyroid gland), radiofrequency ablation, ethanol ablation, and targeted therapies for thyroid cancer. Treatment selection depends on the type & severity of the thyroid disorder and individual patient factors such as age, overall health, and preferences.

MARKET DYNAMICS

The rising incidence of thyroid disorders, including hypothyroidism, hyperthyroidism, and thyroid nodules, drives the demand for effective treatment options to manage symptoms, normalize thyroid hormone levels, and improve patients' quality of life. Factors such as the aging population, iodine deficiency, autoimmune diseases, and environmental pollutants contribute to the increasing burden of thyroid diseases. Additionally, advancements in medical technology and diagnostic tools enable accurate diagnosis and personalized treatment approaches tailored to individual patient needs, driving innovation in thyroid gland disorder treatment modalities. Moreover, the growing emphasis on patient-centric care, shared decision-making, and holistic management approaches in healthcare encourages the adoption of multidisciplinary treatment strategies that combine medication, lifestyle modifications, dietary interventions, and complementary therapies for optimal outcomes.

Furthermore, patient education initiatives, advocacy efforts, and public health campaigns raise awareness about thyroid disorders, symptoms, risk factors, and treatment options, enabling patients to seek timely medical attention and adhere to prescribed treatment regimens. With the increasing recognition of thyroid disorders as a significant public health concern and the growing demand for comprehensive and integrated healthcare services, the thyroid gland disorder treatment market is predicted to continue growing as healthcare providers and pharmaceutical companies innovate to address the evolving needs of patients and improve clinical outcomes. However, regulatory hurdles and safety concerns surrounding new treatment modalities and drug formulations may challenge the growth of the thyroid gland disorder treatment market in the coming years. Additionally, increasing competition from generic alternatives and pricing pressures could impede market expansion.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of thyroid gland disorder treatment. The growth and trends of thyroid gland disorder treatment industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the thyroid gland disorder treatment market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Indication

  • Hypothyroidism
  • Hyperthyroidism

By Route Of Administration

  • Oral
  • Intravenous
  • Others

By Distribution Channel

  • Wholesalers/Distributors
  • Retail Chain
  • Online Distribution
  • Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Thyroid Gland Disorder Treatment market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Thyroid Gland Disorder Treatment market include Abbott, Pfizer, Lannett Company, Inc., GlaxoSmithKline, Merck KGaA, Mylan N.V., AbbVie Inc., Amgen. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Report Description
    • 1.1.1 Objective
    • 1.1.2 Target Audience
    • 1.1.3 Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1 Market Research Process
    • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3. THYROID GLAND DISORDER TREATMENT - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Indication
    • 3.7.2 Market Attractiveness Analysis By Route of Administration
    • 3.7.3 Market Attractiveness Analysis By Distribution Channel
    • 3.7.4 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1 List of Raw Materials
    • 4.2.2 Raw Material Manufactures List
    • 4.2.3 Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1 Direct Marketing
    • 4.4.2 Indirect Marketing
    • 4.4.3 Marketing Channel Development Trend

5. GLOBAL THYROID GLAND DISORDER TREATMENT MARKET ANALYSIS BY INDICATION

  • 5.1. Overview By Indication
  • 5.2. Historical and Forecast Data
  • 5.3. Analysis By Indication
  • 5.4. Hypothyroidism Historic and Forecast Sales By Regions
  • 5.5. Hyperthyroidism Historic and Forecast Sales By Regions

6. GLOBAL THYROID GLAND DISORDER TREATMENT MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

  • 6.1. Overview By Route of Administration
  • 6.2. Historical and Forecast Data
  • 6.3. Analysis By Route of Administration
  • 6.4. Oral Historic and Forecast Sales By Regions
  • 6.5. Intravenous Historic and Forecast Sales By Regions
  • 6.6. Others Historic and Forecast Sales By Regions

7. GLOBAL THYROID GLAND DISORDER TREATMENT MARKET ANALYSIS BY DISTRIBUTION CHANNEL

  • 7.1. Overview By Distribution Channel
  • 7.2. Historical and Forecast Data
  • 7.3. Analysis By Distribution Channel
  • 7.4. Wholesalers/Distributors Historic and Forecast Sales By Regions
  • 7.5. Retail Chain Historic and Forecast Sales By Regions
  • 7.6. Online Distribution Historic and Forecast Sales By Regions
  • 7.7. Others Historic and Forecast Sales By Regions

8. GLOBAL THYROID GLAND DISORDER TREATMENT MARKET ANALYSIS BY GEOGRAPHY

  • 8.1. Regional Outlook
  • 8.2. Introduction
  • 8.3. North America Sales Analysis
    • 8.3.1 Overview, Historic and Forecast Data Sales Analysis
    • 8.3.2 North America By Segment Sales Analysis
    • 8.3.3 North America By Country Sales Analysis
    • 8.3.4 United States Sales Analysis
    • 8.3.5 Canada Sales Analysis
    • 8.3.6 Mexico Sales Analysis
  • 8.4. Europe Sales Analysis
    • 8.4.1 Overview, Historic and Forecast Data Sales Analysis
    • 8.4.2 Europe By Segment Sales Analysis
    • 8.4.3 Europe By Country Sales Analysis
    • 8.4.4 United Kingdom Sales Analysis
    • 8.4.5 France Sales Analysis
    • 8.4.6 Germany Sales Analysis
    • 8.4.7 Italy Sales Analysis
    • 8.4.8 Russia Sales Analysis
    • 8.4.9 Rest Of Europe Sales Analysis
  • 8.5. Asia Pacific Sales Analysis
    • 8.5.1 Overview, Historic and Forecast Data Sales Analysis
    • 8.5.2 Asia Pacific By Segment Sales Analysis
    • 8.5.3 Asia Pacific By Country Sales Analysis
    • 8.5.4 China Sales Analysis
    • 8.5.5 India Sales Analysis
    • 8.5.6 Japan Sales Analysis
    • 8.5.7 South Korea Sales Analysis
    • 8.5.8 Australia Sales Analysis
    • 8.5.9 South East Asia Sales Analysis
    • 8.5.10 Rest Of Asia Pacific Sales Analysis
  • 8.6. Latin America Sales Analysis
    • 8.6.1 Overview, Historic and Forecast Data Sales Analysis
    • 8.6.2 Latin America By Segment Sales Analysis
    • 8.6.3 Latin America By Country Sales Analysis
    • 8.6.4 Brazil Sales Analysis
    • 8.6.5 Argentina Sales Analysis
    • 8.6.6 Peru Sales Analysis
    • 8.6.7 Chile Sales Analysis
    • 8.6.8 Rest of Latin America Sales Analysis
  • 8.7. Middle East & Africa Sales Analysis
    • 8.7.1 Overview, Historic and Forecast Data Sales Analysis
    • 8.7.2 Middle East & Africa By Segment Sales Analysis
    • 8.7.3 Middle East & Africa By Country Sales Analysis
    • 8.7.4 Saudi Arabia Sales Analysis
    • 8.7.5 UAE Sales Analysis
    • 8.7.6 Israel Sales Analysis
    • 8.7.7 South Africa Sales Analysis
    • 8.7.8 Rest Of Middle East And Africa Sales Analysis

9. COMPETITIVE LANDSCAPE OF THE THYROID GLAND DISORDER TREATMENT COMPANIES

  • 9.1. Thyroid Gland Disorder Treatment Market Competition
  • 9.2. Partnership/Collaboration/Agreement
  • 9.3. Merger And Acquisitions
  • 9.4. New Product Launch
  • 9.5. Other Developments

10. COMPANY PROFILES OF THYROID GLAND DISORDER TREATMENT INDUSTRY

  • 10.1. Top Companies Market Share Analysis
  • 10.2. Market Concentration Rate
  • 10.3. Abbott
    • 10.3.1 Company Overview
    • 10.3.2 Company Revenue
    • 10.3.3 Products
    • 10.3.4 Recent Developments
  • 10.4. Pfizer
    • 10.4.1 Company Overview
    • 10.4.2 Company Revenue
    • 10.4.3 Products
    • 10.4.4 Recent Developments
  • 10.5. Lannett Company Inc.
    • 10.5.1 Company Overview
    • 10.5.2 Company Revenue
    • 10.5.3 Products
    • 10.5.4 Recent Developments
  • 10.6. GlaxoSmithKline
    • 10.6.1 Company Overview
    • 10.6.2 Company Revenue
    • 10.6.3 Products
    • 10.6.4 Recent Developments
  • 10.7. Merck KGaA
    • 10.7.1 Company Overview
    • 10.7.2 Company Revenue
    • 10.7.3 Products
    • 10.7.4 Recent Developments
  • 10.8. Mylan N.V.
    • 10.8.1 Company Overview
    • 10.8.2 Company Revenue
    • 10.8.3 Products
    • 10.8.4 Recent Developments
  • 10.9. AbbVie Inc.
    • 10.9.1 Company Overview
    • 10.9.2 Company Revenue
    • 10.9.3 Products
    • 10.9.4 Recent Developments
  • 10.10. Amgen.
    • 10.10.1 Company Overview
    • 10.10.2 Company Revenue
    • 10.10.3 Products
    • 10.10.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies

ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦